Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    992 result(s) found for: Diet. Displaying page 50 of 50.
    «« First « Previous 42  43  44  45  46  47  48  49  50 
    EudraCT Number: 2021-002873-24 Sponsor Protocol Number: RM-493-035 Start Date*: 2022-05-16
    Sponsor Name:Rhythm Pharmaceuticals Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano...
    Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014455-68 Sponsor Protocol Number: HOVON103AMLTosedostat Start Date*: 2010-08-16
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ...
    Medical condition: patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 1...
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10037803 RAEB LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004448-60 Sponsor Protocol Number: 0653A-128 Start Date*: 2007-11-13
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyp...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Completed) IE (Completed) FI (Completed) BE (Completed) DK (Completed) DE (Completed) IT (Completed) AT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004722-16 Sponsor Protocol Number: CLAF237B2224 Start Date*: 2009-03-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) IT (Completed) FI (Completed) SK (Completed) DE (Completed) AT (Completed) LT (Completed) SE (Completed) LV (Completed) BE (Completed) DK (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000294-39 Sponsor Protocol Number: INCB18424-363 Start Date*: 2014-07-16
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who ...
    Medical condition: Advanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033607 Pancreatic cancer recurrent LLT
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) DK (Completed) PT (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002795-41 Sponsor Protocol Number: B1481038 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002646-36 Sponsor Protocol Number: B1481022 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003712-23 Sponsor Protocol Number: CLAF237A23156 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) LV (Completed) IT (Completed) HU (Completed) DE (Completed) EE (Completed) SK (Completed) BG (Completed) PL (Completed) NO (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002095-15 Sponsor Protocol Number: KRX-101-401 Start Date*: 2005-10-12
    Sponsor Name:Keryx Biopharmaceuticals, Inc.
    Full Title: The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy
    Medical condition: Overt Type 2 Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061835 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004340-11 Sponsor Protocol Number: 17403 Start Date*: 2018-06-13
    Sponsor Name:Bayer AG
    Full Title: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or me...
    Medical condition: mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) CZ (Completed) ES (Completed) PT (Completed) FI (Completed) SK (Completed) HU (Completed) DK (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004184-12 Sponsor Protocol Number: DTX401-CL301 Start Date*: 2022-08-22
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia....
    Medical condition: Glycogen Storage Disease Type Ia (GSDIa).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10056911 Glycogen storage disease type IA LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) PT (Completed) DE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002602-52 Sponsor Protocol Number: BAY80-6946/16349 Start Date*: 2012-10-19
    Sponsor Name:Bayer AG
    Full Title: Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas
    Medical condition: Patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas or patients with follicular lymphoma relapsed after or refractory to standard therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029600 Non-Hodgkin's lymphoma recurrent PT
    20.0 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed) SE (Completed) PL (Completed) AT (Completed) PT (Completed) HU (Completed) DK (Prematurely Ended) IE (Completed) GR (Completed) LU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 42  43  44  45  46  47  48  49  50 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 04:24:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA